Quarterly Financial Results and Development Program Updates - Research Report on Regeneron, DaVita, Celldex, Isis, and VIVUS

Quarterly Financial Results and Development Program Updates - Research Report
                on Regeneron, DaVita, Celldex, Isis, and VIVUS

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, August 9, 2013

NEW YORK, August 9, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), DaVita HealthCare Partners Inc.
(NYSE: DVA), Celldex Therapeutics, Inc. (NASDAQ: CLDX), ISIS Pharmaceuticals,
Inc. (NASDAQ: ISIS), and VIVUS, Inc. (NASDAQ: VVUS). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Regeneron Pharmaceuticals Inc. Research Report

On August 6, 2013, Regeneron Pharmaceuticals Inc. (Regeneron) reported its Q2
2013 financial results and provided an update on development programs. The
Company's revenues increased 50.3% YoY to $457.6 million. Net income of $87.4
million or $0.79 per diluted share in Q2 2013, was higher as compared to net
income of $76.7 million or $0.70 per diluted share in Q2 2012. Leonard S.
Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron,
said, "We are pleased with the continued progress of EYLEA both in terms of
commercialization and development in additional indications." He added,
"Today, we reported positive Phase 3 data for EYLEA from the VIVID-DME and
VISTA-DME trials in diabetic macular edema (DME). Based upon discussions with
the U.S. Food & Drug Administration, we now plan to submit a regulatory
application for approval for EYLEA in the DME indication in the U.S. later
this year, approximately one year ahead of our previous plan." The Full
Research Report on Regeneron Pharmaceuticals Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-08-06/REGN]

--

DaVita HealthCare Partners Inc. Research Report

On August 6, 2013, DaVita HealthCare Partners Inc. (DaVita) reported its Q2
2013 results. Total net revenues increased 50.1% YoY to $2.9 billion. Net
income attributable to DaVita was $254.4 million or $2.37 per diluted share in
Q2 2013, compared to $95.3 million or $0.99 per diluted share in Q2 2012. The
Company also revised its consolidated operating income guidance for full-year
2013, and now expects it to be in the range of $1,830 million to $1,930
million, up from its previous guidance range of $1,800 million to $1,900
million. The Full Research Report on DaVita HealthCare Partners Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-08-06/DVA]

--

Celldex Therapeutics, Inc. Research Report

On August 6, 2013, Celldex Therapeutics Inc. (Celldex) reported its Q2 2013
financial results and provided updates on its development programs. The
Company's total revenue declined 95.2% YoY to c.$0.1 million. Net loss was $19
million or $0.24 per diluted share in Q2 2013, compared to a net loss of $13.8
million or $0.23 per diluted share in Q2 2012. Anthony Marucci, President and
Chief Executive Officer of Celldex, said, "In the second quarter, Celldex
continued to advance multiple clinical programs towards key inflection points.
We completed several important steps in preparation for the initiation of our
accelerated approval study of CDX-011 in triple negative breast cancer,
including selecting a diagnostic partner. We also remain pleased with the pace
of enrollment in our Phase 3 study of rindopepimut in frontline glioblastoma
and look forward to presenting data from our Phase 2 study in refractory
glioblastoma at the Society for Neuro-Oncology meeting later this year. In
addition, we enrolled the first patient in our pilot study of CDX-1135 in
dense deposit disease and initiated expansion cohorts in our Phase 1 study of
CDX-1127 in metastatic melanoma and renal cell carcinoma." The Full Research
Report on Celldex Therapeutics, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.investorsreports.com/report/2013-08-06/CLDX]

--

ISIS Pharmaceuticals, Inc. Research Report

On August 6, 2013, ISIS Pharmaceuticals, Inc. (Isis) reported its Q2 2013
financial results. The Company's total revenue decreased 19.5% YoY to $38
million. Net loss was $10.1 million or $0.09 per diluted share in Q2 2013,
compared to a net loss of $1.2 million or $0.01 per diluted share in Q2 2012.
B. Lynne Parshall, Chief Operating Officer of Isis, said, "We ended the
quarter with a significantly improved financial position. We added a new
partner, Roche, for one of our severe and rare disease programs. We advanced
our broad pipeline of drugs, and we reported positive Phase 2 data from our
drug, ISIS-APOCIIIRx. These data support our belief that antisense drugs can
be safe and effective treatments for many different diseases. All of these
activities have significantly contributed to our financial performance this
year and the increase in value of our technology and our drugs in
development."The Full Research Report on ISIS Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-08-06/ISIS]

--

VIVUS, Inc. Research Report

On August 6, 2013, VIVUS, Inc. (VIVUS) reported its Q2 2013 financial
results.Net product revenue from sales of Qsymia, the first FDA-approved once
daily combination therapy for the treatment of obesity, was $5.5 million in Q2
2013. The Company reported net loss of $55.5 million or $0.55 per diluted
share, compared to a net loss of $24 million or $0.24 per diluted share in Q2
2012. VIVUS said that the increased net loss in Q2 2013 as compared to Q2 2012
is primarily attributable to increased selling, general and administrative
expenses related to commercialization activities for Qsymia. The Full Research
Report on VIVUS, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-08-06/VVUS]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Investors' Reports

Contact: Kristi Saunders; +1-315-982-6420 (North America)
 
Press spacebar to pause and continue. Press esc to stop.